Literature DB >> 34913355

Could the CCR5-Delta32 mutation be protective in SARS-CoV-2 infection?

N Starcevic Cizmarevic1, M Kapovic, D Roncevic, S Ristic.   

Abstract

Increasing evidence points to host genetics as a factor in COVID-19 prevalence and outcome. CCR5 is a receptor for proinflammatory chemokines that are involved in host responses, especially to viruses. The CCR5-delta32 minor allele is an interesting variant, given the role of CCR5 in some viral infections, particularly HIV-1. Recent studies of the impact of CCR5-delta32 on COVID-19 risk and severity have yielded contradictory results. This ecologic study shows that the CCR5-delta32 allelic frequency in a European population was significantly negatively correlated with the number of COVID-19 cases (p=0.035) and deaths (p=0.006) during the second pandemic wave. These results suggest that CCR5-delta32 may be protective against SARS-CoV-2 infection, as it is against HIV infection, and could be predictive of COVID-19 risk and severity. Further studies based on samples from populations of different genetic backgrounds are needed to validate these statistically obtained findings.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34913355      PMCID: PMC8884372          DOI: 10.33549/physiolres.934725

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  12 in total

1.  Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers.

Authors:  Ute V Solloch; Kathrin Lang; Vinzenz Lange; Irina Böhme; Alexander H Schmidt; Jürgen Sauter
Journal:  Hum Immunol       Date:  2017-10-05       Impact factor: 2.850

Review 2.  COVID-19 and the immune system.

Authors:  J Paces; Z Strizova; D Smrz; J Cerny
Journal:  Physiol Res       Date:  2020-05-29       Impact factor: 1.881

3.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure.

Authors:  David Ellinghaus; Frauke Degenhardt; Luis Bujanda; Maria Buti; Agustín Albillos; Pietro Invernizzi; Javier Fernández; Daniele Prati; Guido Baselli; Rosanna Asselta; Marit M Grimsrud; Chiara Milani; Fátima Aziz; Jan Kässens; Sandra May; Mareike Wendorff; Lars Wienbrandt; Florian Uellendahl-Werth; Tenghao Zheng; Xiaoli Yi; Raúl de Pablo; Adolfo G Chercoles; Adriana Palom; Alba-Estela Garcia-Fernandez; Francisco Rodriguez-Frias; Alberto Zanella; Alessandra Bandera; Alessandro Protti; Alessio Aghemo; Ana Lleo; Andrea Biondi; Andrea Caballero-Garralda; Andrea Gori; Anja Tanck; Anna Carreras Nolla; Anna Latiano; Anna Ludovica Fracanzani; Anna Peschuck; Antonio Julià; Antonio Pesenti; Antonio Voza; David Jiménez; Beatriz Mateos; Beatriz Nafria Jimenez; Carmen Quereda; Cinzia Paccapelo; Christoph Gassner; Claudio Angelini; Cristina Cea; Aurora Solier; David Pestaña; Eduardo Muñiz-Diaz; Elena Sandoval; Elvezia M Paraboschi; Enrique Navas; Félix García Sánchez; Ferruccio Ceriotti; Filippo Martinelli-Boneschi; Flora Peyvandi; Francesco Blasi; Luis Téllez; Albert Blanco-Grau; Georg Hemmrich-Stanisak; Giacomo Grasselli; Giorgio Costantino; Giulia Cardamone; Giuseppe Foti; Serena Aneli; Hayato Kurihara; Hesham ElAbd; Ilaria My; Iván Galván-Femenia; Javier Martín; Jeanette Erdmann; Jose Ferrusquía-Acosta; Koldo Garcia-Etxebarria; Laura Izquierdo-Sanchez; Laura R Bettini; Lauro Sumoy; Leonardo Terranova; Leticia Moreira; Luigi Santoro; Luigia Scudeller; Francisco Mesonero; Luisa Roade; Malte C Rühlemann; Marco Schaefer; Maria Carrabba; Mar Riveiro-Barciela; Maria E Figuera Basso; Maria G Valsecchi; María Hernandez-Tejero; Marialbert Acosta-Herrera; Mariella D'Angiò; Marina Baldini; Marina Cazzaniga; Martin Schulzky; Maurizio Cecconi; Michael Wittig; Michele Ciccarelli; Miguel Rodríguez-Gandía; Monica Bocciolone; Monica Miozzo; Nicola Montano; Nicole Braun; Nicoletta Sacchi; Nilda Martínez; Onur Özer; Orazio Palmieri; Paola Faverio; Paoletta Preatoni; Paolo Bonfanti; Paolo Omodei; Paolo Tentorio; Pedro Castro; Pedro M Rodrigues; Aaron Blandino Ortiz; Rafael de Cid; Ricard Ferrer; Roberta Gualtierotti; Rosa Nieto; Siegfried Goerg; Salvatore Badalamenti; Sara Marsal; Giuseppe Matullo; Serena Pelusi; Simonas Juzenas; Stefano Aliberti; Valter Monzani; Victor Moreno; Tanja Wesse; Tobias L Lenz; Tomas Pumarola; Valeria Rimoldi; Silvano Bosari; Wolfgang Albrecht; Wolfgang Peter; Manuel Romero-Gómez; Mauro D'Amato; Stefano Duga; Jesus M Banales; Johannes R Hov; Trine Folseraas; Luca Valenti; Andre Franke; Tom H Karlsen
Journal:  N Engl J Med       Date:  2020-06-17       Impact factor: 91.245

4.  SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype.

Authors:  Naoki Yamamoto; Yasuo Ariumi; Nao Nishida; Rain Yamamoto; Georg Bauer; Takashi Gojobori; Kunitada Shimotohno; Masashi Mizokami
Journal:  Gene       Date:  2020-07-03       Impact factor: 3.688

5.  CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.

Authors:  Bruce K Patterson; Harish Seethamraju; Kush Dhody; Michael J Corley; Kazem Kazempour; Jay Lalezari; Alina P S Pang; Christopher Sugai; Eisa Mahyari; Edgar B Francisco; Amruta Pise; Hallison Rodrigues; Helen L Wu; Gabriela M Webb; Byung S Park; Scott Kelly; Nader Pourhassan; Alina Lelic; Lama Kdouh; Monica Herrera; Eric Hall; Benjamin N Bimber; Matthew Plassmeyer; Raavi Gupta; Oral Alpan; Jane A O'Halloran; Philip A Mudd; Enver Akalin; Lishomwa C Ndhlovu; Jonah B Sacha
Journal:  Int J Infect Dis       Date:  2020-11-10       Impact factor: 3.623

6.  CCR5Δ32 mutations do not determine COVID-19 disease course.

Authors:  Stefanie N Bernas; Henning Baldauf; Sarah Wendler; Falk Heidenreich; Vinzenz Lange; Jan A Hofmann; Jürgen Sauter; Alexander H Schmidt; Johannes Schetelig
Journal:  Int J Infect Dis       Date:  2021-03-02       Impact factor: 3.623

7.  Does the CCR5-Δ32 mutation explain the variable coronavirus-2019 pandemic statistics in Europe?

Authors:  Nad Starčević Čizmarević; Marin Tota; Smiljana Ristić
Journal:  Croat Med J       Date:  2020-12-31       Impact factor: 1.351

8.  CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects.

Authors:  J A Hubacek; L Dusek; O Majek; V Adamek; T Cervinkova; D Dlouha; J Pavel; V Adamkova
Journal:  Physiol Res       Date:  2021-03-17       Impact factor: 1.881

Review 9.  Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important?

Authors:  Rajeev K Mehlotra
Journal:  Infect Genet Evol       Date:  2020-08-26       Impact factor: 3.342

Review 10.  Immunobiology and immunotherapy of COVID-19: A clinically updated overview.

Authors:  Abdolreza Esmaeilzadeh; Reza Elahi
Journal:  J Cell Physiol       Date:  2020-10-06       Impact factor: 6.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.